Abstract
Hepatocellular carcinoma (HCC) is the most frequent primary liver cancer, leading to 74.6 thousand deaths annually. The prognosis of HCC over the last few decades has remained unsatisfactory, and over half of patients with early-stage HCC develop recurrence by the time of follow-up. Immunotherapeutic intervention has emerged as a novel, effective treatment to delay the progression of aggressive tumors and suppress tumor recurrence and metastasis. However, few clinical immunotherapy trials have been conducted in HCC patients, and there is an unmet need for novel therapeutic strategies. The combination of conventional treatments with specific immunotherapeutic approaches may dramatically improve the efficacy of HCC treatment and the clinical outcome of HCC patients. In this review, we briefly summarize immunotherapy strategies and discuss new advances in combined immunotherapeutic approaches for the treatment of patients with liver cancer.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Abou-Alfa, G.K., Meyer, T., Cheng, A.L., El-Khoueiry, A.B., Rimassa, L., Ryoo, B.Y., Cicin, I., Merle, P., Chen, Y.H., Park, J.W., et al. (2018). Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N Engl J Med 379, 54–63.
Alnaggar, M., Lin, M., Mesmar, A., Liang, S., Qaid, A., Xu, K., Chen, J., Niu, L., and Yin, Z. (2018). Allogenic natural killer cell immunotherapy combined with irreversible electroporation for stage IV hepatocellular carcinoma: survival outcome. Cell Physiol Biochem 48, 1882–1893.
Bollard, J., Miguela, V., Ruiz de Galarreta, M., Venkatesh, A., Bian, C.B., Roberto, M.P., Tovar, V., Sia, D., Molina-Sanchez, P., Nguyen, C.B., et al. (2017). Palbociclib (PD-0332991), a selective CDK4/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma. Gut 66, 1286–1296.
Brown, S.D., Warren, R.L., Gibb, E.A., Martin, S.D., Spinelli, J.J., Nelson, B.H., and Holt, R.A. (2014). Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival. Genome Res 24, 743–750.
Burki, T.K. (2017). Palbociclib improves survival in advanced breast cancer. Lancet Oncol 18, e1.
Calderaro, J., Rousseau, B., Amaddeo, G., Mercey, M., Charpy, C., Costentin, C., Luciani, A., Zafrani, E.S., Laurent, A., Azoulay, D., et al. (2016). Programmed death ligand 1 expression in hepatocellular carcinoma: relationship with clinical and pathological features. Hepatology 64, 2038–2046.
Chen, C.L., Pan, Q.Z., Zhao, J.J., Wang, Y., Li, Y.Q., Wang, Q.J., Pan, K., Weng, D.S., Jiang, S.S., Tang, Y., et al. (2016). PD-L1 expression as a predictive biomarker for cytokine-induced killer cell immunotherapy in patients with hepatocellular carcinoma. Oncoimmunology 5, e1176653.
Chen, L.T., Chen, M.F., Li, L.A., Lee, P.H., Jeng, L.B., Lin, D.Y., Wu, C.C., Mok, K.T., Chen, C.L., Lee, W.C., et al. (2012). Long-term results of a randomized, observation-controlled, phase III trial of adjuvant interferon Alfa-2b in hepatocellular carcinoma after curative resection. Ann Surg 255, 8–17.
Chen, Y., Ramjiawan, R.R., Reiberger, T., Ng, M.R., Hato, T., Huang, Y., Ochiai, H., Kitahara, S., Unan, E.C., Reddy, T.P., et al. (2015). CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice. Hepatology 61, 1591–1602.
Cui, J., Wang, N., Zhao, H., Jin, H., Wang, G., Niu, C., Terunuma, H., He, H., and Li, W. (2014). Combination of radiofrequency ablation and sequential cellular immunotherapy improves progression-free survival for patients with hepatocellular carcinoma. Int J Cancer 134, 342–351
Duffy, A.G., Ulahannan, S.V., Makorova-Rusher, O., Rahma, O., Wedemeyer, H., Pratt, D., Davis, J.L., Hughes, M.S., Heller, T., ElGindi, M., et al. (2017). Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma. J Hepatol 66, 545–551.
El-Khoueiry, A.B., Sangro, B., Yau, T., Crocenzi, T.S., Kudo, M., Hsu, C., Kim, T.Y., Choo, S.P., Trojan, J., Welling 3rd, T.H., et al. (2017). Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet 389, 2492–2502.
Forner, A., Reig, M., and Bruix, J. (2018). Hepatocellular carcinoma. Lancet 391, 1301–1314.
Gianni, L., Bisagni, G., Colleoni, M., Del Mastro, L., Zamagni, C., Mansutti, M., Zambetti, M., Frassoldati, A., De Fato, R., Valagussa, P., et al. (2018). Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): an exploratory, open-label, phase 2 study. Lancet Oncol 19, 249–256.
Hagel, M., Miduturu, C., Sheets, M., Rubin, N., Weng, W., Stransky, N., Bifulco, N., Kim, J.L., Hodous, B., Brooijmans, N., et al. (2015). First selective small molecule inhibitor of FGFR4 for the treatment of hepatocellular carcinomas with an activated FGFR4 signaling pathway. Cancer Discovery 5, 424–437.
Heo, J., Reid, T., Ruo, L., Breitbach, C.J., Rose, S., Bloomston, M., Cho, M., Lim, H.Y., Chung, H.C., Kim, C.W., et al. (2013). Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nat Med 19, 329–336.
Horwitz, E., Stein, I., Andreozzi, M., Nemeth, J., Shoham, A., Pappo, O., Schweitzer, N., Tornillo, L., Kanarek, N., Quagliata, L., et al. (2014). Human and mouse VEGFA-amplified hepatocellular carcinomas are highly sensitive to sorafenib treatment. Cancer Discovery 4, 730–743.
Inada, Y., Mizukoshi, E., Seike, T., Tamai, T., Iida, N., Kitahara, M., Yamashita, T., Arai, K., Terashima, T., Fushimi, K., et al. (2019). Characteristics of immune response to tumor-associated antigens and immune cell profile in patients with hepatocellular carcinoma. Hepatology 69, 653–665.
Janjigian, Y.Y., Bendell, J., Calvo, E., Kim, J.W., Ascierto, P.A., Sharma, P., Ott, P.A., Peltola, K., Jaeger, D., Evans, J., et al. (2018). CheckMate-032 study: efficacy and safety of nivolumab and nivolumab plus ipilimumab in patients with metastatic esophagogastric cancer. J Clin Oncol 36, 2836–2844.
Le, D.T., Durham, J.N., Smith, K.N., Wang, H., Bartlett, B.R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B.S., et al. (2017). Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 357, 409–413.
Lee, J.H., Lee, J.H., Lim, Y.S., Yeon, J.E., Song, T.J., Yu, S.J., Gwak, G.Y., Kim, K.M., Kim, Y.J., Lee, J.W., et al. (2015). Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma. Gastroenterology 148, 1383–1391.e6.
Lee, J.H., Tak, W.Y., Lee, Y., Heo, M.K., Song, J.S., Kim, H.Y., Park, S.Y., Bae, S.H., Lee, J.H., Heo, J., et al. (2017). Adjuvant immunotherapy with autologous dendritic cells for hepatocellular carcinoma, randomized phase II study. Oncoimmunology 90, e1328335.
Liu, C.Q., Xu, J., Zhou, Z.G., Jin, L.L., Yu, X.J., Xiao, G., Lin, J., Zhuang, S.M., Zhang, Y.J., and Zheng, L. (2018). Expression patterns of programmed death ligand 1 correlate with different microenvironments and patient prognosis in hepatocellular carcinoma. Br J Cancer 119, 80–88.
Llovet, J.M., Sala, M., Castells, L., Suarez, Y., Vilana, R., Bianchi, L., Ayuso, C., Vargas, V., Rodes, J., and Bruix, J. (2000). Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma. Hepatology 31, 54–58.
Llovet, J.M., Zucman-Rossi, J., Pikarsky, E., Sangro, B., Schwartz, M., Sherman, M., and Gores, G. (2016). Hepatocellular carcinoma. Nat Rev Dis Primers 2, 16018.
Long, G.V., Atkinson, V., Lo, S., Sandhu, S., Guminski, A.D., Brown, M.P., Wilmott, J.S., Edwards, J., Gonzalez, M., Scolyer, R.A., et al. (2018). Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. Lancet Oncol 19, 672–681.
Mazzaferro, V., Romito, R., Schiavo, M., Mariani, L., Camerini, T., Bhoori, S., Capussotti, L., Calise, F., Pellicci, R., Belli, G., et al. (2006). Prevention ofhepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. Hepatology 44, 1543–1554.
Mazzolini, G., Alfaro, C., Sangro, B., Feijoó, E., Ruiz, J., Benito, A., Tirapu, I., Arina, A., Sola, J., Herraiz, M., et al. (2005). Intratumoral injection of dendritic cells engineered to secrete interleukin-12 by recombinant adenovirus in patients with metastatic gastrointestinal carcinomas. J Clin Oncol 23, 999–1010.
McGranahan, N., Furness, A.J.S., Rosenthal, R., Ramskov, S., Lyngaa, R., Saini, S.K., Jamal-Hanjani, M., Wilson, G.A., Birkbak, N.J., Hiley, C. T., et al. (2016). Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science 351, 1463–1469.
Motzer, R.J., Tannir, N.M., McDermott, D.F., Aren Frontera, O., Melichar, B., Choueiri, T.K., Plimack, E.R., Barthelemy, P., Porta, C., George, S., et al. (2018). Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med 378, 1277–1290.
Murawski, M., Weeda, V.B., Maibach, R., Morland, B., Roebuck, D.J., Zimmerman, A., Casanova, M., Perilongo, G., Laithier, V., Kebudi, R., et al. (2016). Hepatocellular carcinoma in children: does modified platinum- and doxorubicin-based chemotherapy increase tumor resectability and change outcome? lessons learned from the SIOPEL 2 and 3 studies. J Clin Oncol 34, 1050–1056.
O’Leary, B., Finn, R.S., and Turner, N.C. (2016). Treating cancer with selective CDK4/6 inhibitors. Nat Rev Clin Oncol 13, 417–430.
Qin, S., Bai, Y., Lim, H.Y., Thongprasert, S., Chao, Y., Fan, J., Yang, T.S., Bhudhisawasdi, V., Kang, W.K., Zhou, Y., et al. (2013). Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia. J Clin Oncol 31, 3501–3508.
Rizvi, N.A., Hellmann, M.D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J.J., Lee, W., Yuan, J., Wong, P., Ho, T.S., et al. (2015). Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348, 124–128.
Sangro, B., Gomez-Martin, C., de la Mata, M., Inarrairaegui, M., Garralda, E., Barrera, P., Riezu-Boj, J.I., Larrea, E., Alfaro, C., Sarobe, P., et al. (2013). A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. J Hepatol 59, 81–88.
Sawada, Y., Yoshikawa, T., Ofuji, K., Yoshimura, M., Tsuchiya, N., Takahashi, M., Nobuoka, D., Gotohda, N., Takahashi, S., Kato, Y., et al. (2016). Phase II study of the GPC3-derived peptide vaccine as an adjuvant therapy for hepatocellular carcinoma patients. Oncoimmunology 5, e1129483.
Schulze, K., Imbeaud, S., Letouze, E., Alexandrov, L.B., Calderaro, J., Rebouissou, S., Couchy, G., Meiller, C., Shinde, J., Soysouvanh, F., et al. (2015). Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. Nat Genet 47, 505–511.
Sherr, C.J. (2016). A new cell-cycle target in cancer—inhibiting cyclin D-dependent kinases 4 and 6. N Engl J Med 375, 1920–1923.
Shi, L., Lin, H., Li, G., Sun, Y., Shen, J., Xu, J., Lin, C., Yeh, S., Cai, X., and Chang, C. (2016). Cisplatin enhances NK cells immunotherapy efficacy to suppress HCC progression via altering the androgen receptor (AR)-ULBP2 signals. Cancer Lett 373, 45–56.
Shim, J.H., Jun, M.J., Han, S., Lee, Y.J., Lee, S.G., Kim, K.M., Lim, Y.S., and Lee, H.C. (2015). Prognostic nomograms for prediction of recurrence and survival after curative liver resection for hepatocellular carcinoma. Ann Surg 261, 939–946.
Sideras, K., Biermann, K., Verheij, J., Takkenberg, B.R., Mancham, S., Hansen, B.E., Schutz, H.M., de Man, R.A., Sprengers, D., Buschow, S. I., et al. (2017). PD-L1, Galectin-9 and CD8+ tumor-infiltrating lymphocytes are associated with survival in hepatocellular carcinoma. Oncoimmunology 6, e1273309.
Simonelli, M., Zucali, P., Santoro, A., Thomas, M.B., de Braud, F.G., Borghaei, H., Berlin, J., Denlinger, C.S., Noberasco, C., Rimassa, L., et al. (2016). Phase I study of PF-03446962, a fully human monoclonal antibody against activin receptor-like kinase-1, in patients with hepatocellular carcinoma. Ann Oncol 27, 1782–1787.
Takayama, T., Sekine, T., Makuuchi, M., Yamasaki, S., Kosuge, T., Yamamoto, J., Shimada, K., Sakamoto, M., Hirohashi, S., Ohashi, Y., et al. (2000). Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet 356, 802–807.
Totoki, Y., Tatsuno, K., Covington, K.R., Ueda, H., Creighton, C.J., Kato, M., Tsuji, S., Donehower, L.A., Slagle, B.L., Nakamura, H., et al. (2014). Trans-ancestry mutational landscape of hepatocellular carcinoma genomes. Nat Genet 46, 1267–1273.
Tumeh, P.C., Harview, C.L., Yearley, J.H., Shintaku, I.P., Taylor, E.J.M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014). PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515, 568–571.
Ueno, M., Hayami, S., Shigekawa, Y., Kawai, M., Hirono, S., Okada, K., Tamai, H., Shingaki, N., Mori, Y., Ichinose, M., et al. (2015). Prognostic impact of surgery and radiofrequency ablation on single nodular HCC 5 cm: Cohort study based on serum HCC markers. J Hepatol 63, 1352–1359.
Van Allen, E.M., Miao, D., Schilling, B., Shukla, S.A., Blank, C., Zimmer, L., Sucker, A., Hillen, U., Geukes Foppen, M.H., Goldinger, S.M., et al. (2015). Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science 350, 207–211.
Wang, H., Liu, A., Bo, W., Feng, X., Hu, Y., Tian, L., Zhang, H., and Tang, X. (2016). Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma patients after curative resection, a systematic review and meta-analysis. Digest Liver Dis 48, 1275–1282.
Yang, Y., Zhou, Y., Hou, J., Bai, C., Li, Z., Fan, J., Ng, I.O.L., Zhou, W., Sun, H., Dong, Q., et al. (2017). Hepatic IFIT3 predicts interferon-α therapeutic response in patients of hepatocellular carcinoma. Hepatology 66, 152–166.
Zhou, J., Liu, M., Sun, H., Feng, Y., Xu, L., Chan, A.W.H., Tong, J.H., Wong, J., Chong, C.C.N., Lai, P.B.S., et al. (2018). Hepatoma-intrinsic CCRK inhibition diminishes myeloid-derived suppressor cell immunosuppression and enhances immune-checkpoint blockade efficacy. Gut 67, 931–944.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Compliance and ethics The author(s) declare that they have no conflict of interest.
Rights and permissions
About this article
Cite this article
Tian, M., Shi, Y., Liu, W. et al. Immunotherapy of hepatocellular carcinoma: strategies for combinatorial intervention. Sci. China Life Sci. 62, 1138–1143 (2019). https://doi.org/10.1007/s11427-018-9446-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11427-018-9446-2